CLINICALLY ACHIEVABLE PLASMA DEFEROXAMINE CONCENTRATIONS ARE THERAPEUTIC IN A RAT MODEL OF PNEUMOCYSTIS-CARINII PNEUMONIA

被引:17
作者
MERALI, S
CHIN, K
DELANGEL, L
GRADY, RW
ARMSTRONG, M
CLARKSON, AB
机构
[1] NYU, SCH MED, DEPT MED & MOLEC PARASITOL, NEW YORK, NY 10016 USA
[2] CORNELL UNIV, COLL MED, DEPT PEDIAT, NEW YORK, NY 10021 USA
关键词
D O I
10.1128/AAC.39.9.2023
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The iron-chelating drug deferoxamine (DFO) has been shown to be active in animal models of Pneumocystis carinii pneumonia (PCP), with effective daily intraperitoneal bolus dosages being 400 and 1,000 mg of DFO mesylate kg of body weight(-1) in mouse and rat models, respectively. Continuous infusion produced a moderately improved response in a rat model. The data reported here demonstrate that the response achieved by continuous infusion of 195 and 335 mg of DFO mesylate kg(-1) day(-1) in the rat model is associated with mean concentrations in plasma of 1.3 and 2.5 mu g of DFO ml(-1) and mean concentrations in lung tissue of 4.9 and 6.0 mu g of DFO g of lung tissue(-1), respectively. Since current clinical use of DFO mesylate for the treatment of iron overload produces higher concentrations in the plasma of patients, DFO may prove to be a useful anti-PCP treatment. The 2.4- to 3.8-fold higher DFO concentration observed in lung tissue compared with that observed in plasma may be important in the response of PCP to DFO.
引用
收藏
页码:2023 / 2026
页数:4
相关论文
共 21 条
[1]   DEFEROXAMINE INCREASES SKIN FLAP SURVIVAL - ADDITIONAL EVIDENCE OF FREE-RADICAL INVOLVEMENT IN ISCHEMIC FLAP SURGERY [J].
ANGEL, MF ;
NARAYANAN, K ;
SWARTZ, WM ;
RAMASASTRY, SS ;
KUHNS, DB ;
BASFORD, RE ;
FUTRELL, JW .
BRITISH JOURNAL OF PLASTIC SURGERY, 1986, 39 (04) :469-472
[2]   EFFECT OF AN IRON-CHELATING AGENT ON LYMPHOCYTE-PROLIFERATION [J].
BOWERN, N ;
RAMSHAW, IA ;
BADENOCHJONES, P ;
DOHERTY, PC .
AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1984, 62 (DEC) :743-754
[3]   DESFERRIOXAMINE TREATMENT PREVENTS CHRONIC ISLET ALLOGRAFT DAMAGE [J].
BRADLEY, B ;
PROWSE, SJ ;
BAULING, P ;
LAFFERTY, KJ .
DIABETES, 1986, 35 (05) :550-555
[4]   DEFEROXAMINE AND EFLORNITHINE (DL-ALPHA-DIFLUOROMETHYLORNITHINE) IN A RAT MODEL OF PNEUMOCYSTIS-CARINII PNEUMONIA [J].
CLARKSON, AB ;
SARIC, M ;
GRADY, RW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) :1833-1835
[5]   RECENT ADVANCES IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA [J].
DAVEY, RT ;
MASUR, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) :499-504
[6]  
FUDMAN EJ, 1987, J RHEUMATOL, V14, P686
[7]  
GORDEUK VR, 1994, ADV EXP MED BIOL, V356, P371
[8]   IRON CHELATION [J].
HERSHKO, C ;
PINSON, A ;
LINK, G .
BLOOD REVIEWS, 1990, 4 (01) :1-8
[9]  
HERSHKO C, 1990, CLIN HEMATOL, V2, P293
[10]   PNEUMOCYSTIS-CARINII PNEUMONIA - A COMPARISON BETWEEN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME AND PATIENTS WITH OTHER IMMUNODEFICIENCIES [J].
KOVACS, JA ;
HIEMENZ, JW ;
MACHER, AM ;
STOVER, D ;
MURRAY, HW ;
SHELHAMER, J ;
LANE, HC ;
URMACHER, C ;
HONIG, C ;
LONGO, DL ;
PARKER, MM ;
NATANSON, C ;
PARRILLO, JE ;
FAUCI, AS ;
PIZZO, PA ;
MASUR, H .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :663-671